Kyowa Kirin to Acquire Orchard Therapeutics

-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables...

Related Keywords

Japan ,Boston ,Massachusetts ,United States ,Italy ,United Kingdom ,Norway ,Tokyo ,Liechtenstein ,Iceland ,Milan ,Lombardia ,London ,City Of ,American ,America ,Lisa Popyk ,Stacey Minton ,Bobby Gaspar ,Takeyoshi Yamashita ,Benjamin Navon ,Hiroki Nakamura ,Asia Pacific ,Telethon Institute For Gene Therapy ,Party Status ,Globenewswire Inc ,Regulatory Agency ,San Raffaele Telethon Institute For Gene Therapy ,High Court ,Drug Administration ,Goodwin Procter ,Orchard Therapeutics Europe ,Linkedin ,America Corporate Communications ,Nasdaq ,Exchange Commission ,Corporate Communications Department ,Slaughter May Ltd ,Goldman Sachs Japan Co Ltd ,Kyowa Kirin International ,Morrison Foerster Llp ,European Commission ,Orchard Investor Relations Department ,Zentree Investment Management Pte Ltd ,European Union ,Morrison Foerster ,Global Specialty Pharmaceutical Company ,Kyowa Kirin Co Ltd ,Corporate Affairs ,Guggenheim Securities ,Kyowa Kirin ,American Depositary Share ,Kingdom Medicines ,Priority Review ,Prescription Drug User Fee Act ,Orchard Therapeutic ,Transaction Agreement ,Investment Management Pte Ltd ,Specialty Pharmaceutical Company ,Raffaele Telethon Institute ,Gene Therapy ,Product Characteristics ,Proxy Statement ,Investor Relations Department ,Securities Act ,Annual Report ,Quarterly Reports ,Current Reports ,Quarterly Report ,Kirin Hiroki Nakamura ,Markets ,